152 related articles for article (PubMed ID: 27004541)
1. A comparison of genetic risk score with family history for estimating prostate cancer risk.
Helfand BT
Asian J Androl; 2016; 18(4):515-9. PubMed ID: 27004541
[TBL] [Abstract][Full Text] [Related]
2. Clinical validity and utility of genetic risk scores in prostate cancer.
Helfand BT; Kearns J; Conran C; Xu J
Asian J Androl; 2016; 18(4):509-14. PubMed ID: 27297129
[TBL] [Abstract][Full Text] [Related]
3. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
[TBL] [Abstract][Full Text] [Related]
4. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
Chen H; Liu X; Brendler CB; Ankerst DP; Leach RJ; Goodman PJ; Lucia MS; Tangen CM; Wang L; Hsu FC; Sun J; Kader AK; Isaacs WB; Helfand BT; Zheng SL; Thompson IM; Platz EA; Xu J
Prostate; 2016 Sep; 76(12):1120-9. PubMed ID: 27197965
[TBL] [Abstract][Full Text] [Related]
5. Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.
Conran CA; Na R; Chen H; Jiang D; Lin X; Zheng SL; Brendler CB; Xu J
Asian J Androl; 2016; 18(4):520-4. PubMed ID: 27080480
[TBL] [Abstract][Full Text] [Related]
6. Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.
Na R; Ye D; Qi J; Liu F; Lin X; Helfand BT; Brendler CB; Conran C; Gong J; Wu Y; Gao X; Chen Y; Zheng SL; Mo Z; Ding Q; Sun Y; Xu J
Asian J Androl; 2016; 18(4):525-9. PubMed ID: 27140652
[TBL] [Abstract][Full Text] [Related]
7. Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.
Helfand BT; Chen H; Fantus RJ; Conran CA; Brendler CB; Zheng SL; Walsh PC; Isaacs WB; Xu J
Prostate; 2018 Jun; ():. PubMed ID: 29923209
[TBL] [Abstract][Full Text] [Related]
8. Germline Genetics of Prostate Cancer: Time to Incorporate Genetics into Early Detection Tools.
Fantus RJ; Helfand BT
Clin Chem; 2019 Jan; 65(1):74-79. PubMed ID: 30459162
[TBL] [Abstract][Full Text] [Related]
9. Genetic factors influencing prostate cancer risk in Norwegian men.
Chen H; Ewing CM; Zheng S; Grindedaal EM; Cooney KA; Wiley K; Djurovic S; Andreassen OA; Axcrona K; Mills IG; Xu J; Maehle L; Fosså SD; Isaacs WB
Prostate; 2018 Feb; 78(3):186-192. PubMed ID: 29181843
[TBL] [Abstract][Full Text] [Related]
10. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
11. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.
Shi Z; Platz EA; Wei J; Na R; Fantus RJ; Wang CH; Eggener SE; Hulick PJ; Duggan D; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Xu J
Eur Urol; 2021 Mar; 79(3):419-426. PubMed ID: 33257031
[TBL] [Abstract][Full Text] [Related]
12. Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
Liss MA; Xu J; Chen H; Kader AK
Prostate; 2015 Sep; 75(12):1322-8. PubMed ID: 25982801
[TBL] [Abstract][Full Text] [Related]
13. Concept and benchmarks for assessing narrow-sense validity of genetic risk score values.
Yu H; Shi Z; Wu Y; Wang CH; Lin X; Perschon C; Isaacs WB; Helfand BT; Lilly Zheng S; Duggan D; Mo Z; Lu D; Xu J
Prostate; 2019 Jul; 79(10):1099-1105. PubMed ID: 31037745
[TBL] [Abstract][Full Text] [Related]
14. Estimation of absolute risk for prostate cancer using genetic markers and family history.
Xu J; Sun J; Kader AK; Lindström S; Wiklund F; Hsu FC; Johansson JE; Zheng SL; Thomas G; Hayes RB; Kraft P; Hunter DJ; Chanock SJ; Isaacs WB; Grönberg H
Prostate; 2009 Oct; 69(14):1565-72. PubMed ID: 19562736
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer risk-associated genetic markers and their potential clinical utility.
Xu J; Sun J; Zheng SL
Asian J Androl; 2013 May; 15(3):314-22. PubMed ID: 23564047
[TBL] [Abstract][Full Text] [Related]
16. Association Between the Body Mass Index and Prostate Cancer at Biopsy is Modified by Genetic Risk: A Cross-Sectional Analysis in China.
Zhang GM; Zhu Y; Chen HT; Han CT; Liu F; Xu JF; Ye DW
Medicine (Baltimore); 2015 Oct; 94(42):e1603. PubMed ID: 26496266
[TBL] [Abstract][Full Text] [Related]
17. Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
Chen H; Na R; Packiam VT; Conran CA; Jiang D; Tao S; Yu H; Lin X; Meng W; Zheng SL; Brendler CB; Helfand BT; Xu J
Prostate; 2017 Aug; 77(11):1179-1186. PubMed ID: 28670847
[TBL] [Abstract][Full Text] [Related]
18. Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment.
Yu H; Shi Z; Lin X; Bao Q; Jia H; Wei J; Helfand BT; Zheng SL; Duggan D; Lu D; Mo Z; Xu J
Prostate; 2020 Jan; 80(1):83-87. PubMed ID: 31634418
[TBL] [Abstract][Full Text] [Related]
19. Association of THADA, FOXP4, GPRC6A/RFX6 genes and 8q24 risk alleles with prostate cancer in Northern Chinese men.
Li XH; Xu Y; Yang K; Shi JJ; Zhang X; Yang F; Yuan H; Zhu X; Zhang YH; Wang JY; Yang Z
J BUON; 2015; 20(5):1223-8. PubMed ID: 26537068
[TBL] [Abstract][Full Text] [Related]
20. Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?
Butoescu V; Ambroise J; Stainier A; Dekairelle AF; Gala JL; Tombal B
Prostate; 2014 Apr; 74(4):365-71. PubMed ID: 24265090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
